港股異動 | 歌禮制藥大漲近15%,新冠口服藥獲積極I期臨牀結果
智通財經APP獲悉,$歌禮制藥-B(01672.HK)$早盤高開,截至發稿,現漲近15%,成交額超300萬港元。
消息面上,歌禮制藥公佈,新冠口服聚合酶(RdRp)抑制劑ASC10在健康受試者中的多劑量遞增(MAD)I期研究取得積極頂線數據。I期數據顯示,所有劑量的ASC10在中國受試者中安全性及耐受性良好。ASC10治療組和安慰劑治療組的安全性數據相似。
據悉,活性藥物ASC10-A對多種奧密克戎變種病毒如BA.5和BA.2.75具有強效的抗病毒活性。歌禮已在全球範圍內提交了多項ASC10及其用途的專利申請。用於該項臨牀研究的ASC10口服片劑是歌禮專有技術開發的產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.